Page last updated: 2024-11-10

nefurthiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

nefurthiazole: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3607071
CHEMBL ID84011
CHEBI ID82328
SCHEMBL ID194337
MeSH IDM0041365

Synonyms (45)

Synonym
chebi:82328 ,
CHEMBL84011
n'-[4-(5-nitrofuran-2-yl)-1,3-thiazol-2-yl]formic hydrazide
nifurthiazole [usan:inn]
brn 0551526
hydrazinecarboxaldehyde, 2-(4-(5-nitro-2-furanyl)-2-thiazolyl)-
formic acid, 2-(4-(5-nitro-2-furyl)-2-thiazolyl)hydrazide
formic 2-(4-(5-nitrofuryl)-2-thiazolyl)hydrazide
hsdb 2943
ccris 433
formic acid 2-(4-(5-nitro-2-furyl)-2-thiazolyl)hydrazide
nifurtiazol [inn-spanish]
nifurthiazolum [inn-latin]
D05167
nifurthiazole (usan/inn)
FNT ,
hydrazinecarboxaldehyde, 2-[4-(5-nitro-2-furanyl)-2-thiazolyl)-
3570-75-0
wln: t5oj bnw e- et5n csj bmmvh
nefurthiazole
nsc525334
nifurthiazol
nifurthiazole
as 17665
nsc-525334
hydrazinecarboxaldehyde, 2-[4-(5-nitro-2-furanyl)-2-thiazolyl]-
formic acid, 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide
2-(2-formylhydrazino)-4-(5-nitro-2-furyl)thiazole
formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide
as-17665 ,
formic acid, 2-[4-(5-nitro-2-furyl)-2-thiazolylhydrazide
n-[[4-(5-nitrofuran-2-yl)-1,3-thiazol-2-yl]amino]formamide
C19240
nifurtiazol
unii-76c4hve5l9
nifurthiazolum
76c4hve5l9 ,
2-(4-(5-nitro-2-furyl)-2-thiazolyl)formic acid hydrazide
nifurthiazole [hsdb]
nifurthiazole [usan]
nifurthiazole [inn]
SCHEMBL194337
formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl]-hydrazide
DTXSID6020640
Q27155878
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
furansCompounds containing at least one furan ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID168110Carcinogenic activity on other sites after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID318681Anticarcinogenic activity in rat assessed as induction of tumors per day2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
QSAR modeling of the rodent carcinogenicity of nitrocompounds.
AID168085Carcinogenic activity on liver after oral administration of the compound1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID167938Carcinogenic activity on breast after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID167927Carcinogenic activity on all sites after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID167951Carcinogenic activity on ear duct after oral administration of the compound; - denotes non carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (87.50)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]